Skip to main content

Table 1 Baseline characteristics of the European and Japanese trial populations (full analysis sets)

From: Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials

 

European population [23]

Japanese population [24]

 

DNG (n = 120)

GnRH analogue (n = 128)

DNG (n = 128)

GnRH analogue (n = 125)

Age (years, mean ± SD)

30.6 ± 6.2

31.0 ± 5.8

33.5 ± 6.9

33.8 ± 6.2

Weight (kg, mean ± SD)

62.5 ± 10.8

62.7 ± 9.6

52.1 ± 7.1

53.3 ± 8.2

Lumbar BMD (g/cm2, mean ± SD)

1.06 ± 0.1 (n = 26)

1.07 ± 0.1 (n = 31)

1.04 ± 0.1 (n = 41)

1.03 ± 0.1 (n = 46)

  1. DNG, dienogest (2 mg/day); GnRH, gonadotropin-releasing hormone analogue; BMD, bone mineral density. GnRH analogues: European trial, leuprolide acetate 3.75 mg intramuscular injection, four-weekly; Japanese trial, buserelin acetate 3 × 300 μg/day, intranasally.